Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*

無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

INSIDE INFORMATION DELISTING OF STA UPDATE ON DELISTING APPLICATION BY STA

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the "Company") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Reference is made to the announcements of the Company dated March 10, 2019, April 4, 2019, April 18, 2019, April 25, 2019 and May 10, 2019 in relation to the Proposed Delisting of STA (the "Announcements"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

According to the Letter regarding the Approval for the Delisting of Shanghai SynTheAll Pharmaceutical Co., Ltd.* from the National Equities Exchange and Quotations (Gu Zhuan Xi Tong Han [2019] No. 2340) (《關於同意上海合全藥業股份有限公司股票終止在全國中小企業股份轉讓系統掛牌的函》(股轉系統函 [2019]2340 號)) issued by NEEQ on June 24, 2019, the shares of STA will be delisted from NEEQ on June 26, 2019. For details, please refer to the relevant announcement disclosed by STA on the website of NEEQ (http://www.neeq.com.cn/). The delisting of the shares of STA will not have any adverse effect on the daily operations of the Company.

By order of the Board
WuXi AppTec Co., Ltd.
Dr. Ge Li
Chairman

Hong Kong, June 25, 2019

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* For identification purpose only